Related Experiment Video
Updated: Aug 7, 2025

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Modelling the impact of CD4 testing on mortality from TB and cryptococcal meningitis among patients with advanced HIV
Ikwo Kitefre Oboho1, Heather Paulin1, Carl Corcoran1
1Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Insights
Baseline CD4 testing helps prevent deaths from tuberculosis and cryptococcal meningitis in people with advanced HIV disease starting antiretroviral therapy. Retaining CD4 testing averts significant mortality, though resource allocation requires careful consideration.
Area of Science:
- Infectious Diseases
- Public Health
- Immunology
Background:
- Antiretroviral therapy (ART) scale-up has not eliminated opportunistic infections in people living with HIV (PLHIV) with advanced HIV disease (AHD).
- The shift to viral load testing has reduced the identification of AHD, increasing mortality risk.
- Opportunistic infections like tuberculosis (TB) and cryptococcal meningitis (CM) remain leading causes of death in AHD patients.
Purpose of the Study:
- To project deaths from TB and CM among PLHIV initiating ART with CD4 <200 cells/mm³.
- To evaluate the impact of baseline CD4 testing on averting deaths from TB and CM.
- To compare projected mortality with and without CD4 testing in nine African countries.
Main Methods:
- Utilized official estimates and epidemiological data for projections.
- Modeled the reduction in deaths based on diagnostic and therapeutic protocol performance.
- Compared projected TB and CM deaths in the first year of ART (2019-2024) with and without CD4 testing.
Main Results:
- CD4 testing algorithms avert 31% to 38% of TB and CM deaths in the first year of ART.
- The number of CD4 tests needed per death averted varies significantly by country.
- South Africa requires approximately 101 CD4 tests per death averted, while Kenya requires 917.
Conclusions:
- Retaining baseline CD4 testing is crucial for averting deaths from TB and CM in AHD patients.
- National programs must balance the cost of CD4 testing access with other HIV priorities.
- Resource allocation for CD4 testing should be carefully considered within broader HIV strategies.
Introduction:
Despite antiretroviral therapy (ART) scale-up among people living with HIV (PLHIV), those with advanced HIV disease (AHD) (defined in adults as CD4 count <200 cells/mm3 or clinical stage 3 or 4), remain at high risk of death from opportunistic infections. The shift from routine baseline CD4 testing towards viral load testing in conjunction with "Test and Treat" has limited AHD identification.
Methods:
We used official estimates and existing epidemiological data to project deaths from tuberculosis (TB) and cryptococcal meningitis (CM) among PLHIV-initiating ART with CD4 <200 cells/mm3 , in the absence of select World Health Organization recommended diagnostic or therapeutic protocols for patients with AHD. We modelled the reduction in deaths, based on the performance of screening/diagnostic testing and the coverage and efficacy of treatment/preventive therapies for TB and CM. We compared projected TB and CM deaths in the first year of ART from 2019 to 2024, with and without CD4 testing. The analysis was performed for nine countries: South Africa, Kenya, Lesotho, Mozambique, Nigeria, Uganda, Zambia, Zimbabwe and the Democratic Republic of Congo.
Results:
The effect of CD4 testing comes through increased identification of AHD and consequent eligibility for protocols for AHD prevention, diagnosis and management; algorithms for CD4 testing avert between 31% and 38% of deaths from TB and CM in the first year of ART. The number of CD4 tests required per death averted varies widely by country from approximately 101 for South Africa to 917 for Kenya.
Conclusions:
This analysis supports retaining baseline CD4 testing to avert deaths from TB and CM, the two most deadly opportunistic infections among patients with AHD. However, national programmes will need to weigh the cost of increasing CD4 access against other HIV-related priorities and allocate resources accordingly.
More Related Videos
09:02An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
Published on: February 17, 2014
08:14An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Published on: October 6, 2015
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Retrovirus Life Cycles